All terms in MESH
| Label | Id | Description |
|---|---|---|
| CD4 Lymphocyte Count | D018791 | [The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer.] |
| thiersinine B | C471500 | |
| thiersinine A | C471501 | |
| Neurofibromatosis 2 | D016518 | [An autosomal dominant disorder characterized by a high incidence of bilateral acoustic neuromas as well as schwannomas (NEURILEMMOMA) of other cranial and peripheral nerves, and other benign intracranial tumors including meningiomas, ependymomas, spinal neurofibromas, and gliomas. The disease has been linked to mutations of the NF2 gene (GENES, NEUROFIBROMATOSIS 2) on chromosome 22 (22q12) and usually presents clinically in the first or second decade of life.] |
| Neuroma, Acoustic | D009464 | [A benign SCHWANNOMA of the eighth cranial nerve (VESTIBULOCOCHLEAR NERVE), mostly arising from the vestibular branch (VESTIBULAR NERVE) during the fifth or sixth decade of life. Clinical manifestations include HEARING LOSS; HEADACHE; VERTIGO; TINNITUS; and FACIAL PAIN. Bilateral acoustic neuromas are associated with NEUROFIBROMATOSIS 2. (From Adams et al., Principles of Neurology, 6th ed, p673)] |
| Neurofibromatoses | D017253 | [A group of disorders characterized by an autosomal dominant pattern of inheritance with high rates of spontaneous mutation and multiple neurofibromas or neurilemmomas. NEUROFIBROMATOSIS 1 (generalized neurofibromatosis) accounts for approximately 95% of cases, although multiple additional subtypes (e.g., NEUROFIBROMATOSIS 2, neurofibromatosis 3, etc.) have been described. (From Neurochirurgie 1998 Nov;44(4):267-72)] |
| 2,7-bis(1H-pyrrol-2-yl)ethynyl-1,8-naphthyridine | C471502 | |
| Hospitals, Religious | D016519 | [Private hospitals that are owned or sponsored by religious organizations.] |
| Hospitals, Private | D016304 | [A class of hospitals that includes profit or not-for-profit hospitals that are controlled by a legal entity other than a government agency. (Hospital Administration Terminology, AHA, 2d ed)] |
| dimethyl 1,2-corannulene dicarboxylate | C471503 | |
| hypoxyxylerone | C471504 | |
| apiole | C446539 | |
| phospholipase D delta | C446530 | |
| HPT1 protein, Arabidopsis | C446531 | |
| Entrepreneurship | D016520 | [The organization, management, and assumption of risks of a business or enterprise, usually implying an element of change or challenge and a new opportunity.] |
| Commerce | D003132 | [The interchange of goods or commodities, especially on a large scale, between different countries or between populations within the same country. It includes trade (the buying, selling, or exchanging of commodities, whether wholesale or retail) and business (the purchase and sale of goods to make a profit). (From Random House Unabridged Dictionary, 2d ed, p411, p2005 & p283)] |
| Organizational Innovation | D009936 | [Introduction of changes which are new to the organization and are created by management.] |
| Electrophoresis, Gel, Pulsed-Field | D016521 | [Gel electrophoresis in which the direction of the electric field is reversed periodically., Gel electrophoresis in which the application of the electric field is alternated between two perpendicular directions., Gel electrophoresis in which the direction of the electric field is changed periodically. This technique is similar to other electrophoretic methods normally used to separate double-stranded DNA molecules ranging in size up to tens of thousands of base-pairs. However, by alternating the electric field direction one is able to separate DNA molecules up to several million base-pairs in length., Gel electrophoresis in which the angle of the electric field is changed periodically.] |
| Electrophoresis | D004586 | [An electrochemical process in which macromolecules or colloidal particles with a net electric charge migrate in a solution under the influence of an electric current.] |
| Oncology Service, Hospital | D016522 | [The hospital department responsible for the administration and provision of diagnostic and therapeutic services for the cancer patient.] |